Shares of Prothena Co. plc (NASDAQ:PRTA - Get Free Report) gapped up prior to trading on Monday . The stock had previously closed at $15.30, but opened at $16.22. Prothena shares last traded at $17.97, with a volume of 302,186 shares trading hands.
Analyst Upgrades and Downgrades
Several research analysts have recently weighed in on PRTA shares. Royal Bank of Canada lowered their target price on Prothena from $28.00 to $24.00 and set a "sector perform" rating on the stock in a report on Friday, August 9th. Oppenheimer reduced their price target on Prothena from $66.00 to $62.00 and set an "outperform" rating on the stock in a report on Wednesday, August 14th. Cantor Fitzgerald restated an "overweight" rating on shares of Prothena in a research report on Monday, September 30th. StockNews.com upgraded shares of Prothena from a "sell" rating to a "hold" rating in a report on Monday, August 12th. Finally, Bank of America cut their price target on shares of Prothena from $33.00 to $31.00 and set a "neutral" rating for the company in a report on Tuesday, October 1st. Three analysts have rated the stock with a hold rating and five have given a buy rating to the stock. According to MarketBeat, Prothena has a consensus rating of "Moderate Buy" and an average target price of $61.86.
Check Out Our Latest Analysis on PRTA
Prothena Stock Up 15.0 %
The firm's fifty day moving average price is $19.47 and its 200 day moving average price is $20.76.
Prothena (NASDAQ:PRTA - Get Free Report) last released its quarterly earnings results on Thursday, August 8th. The biotechnology company reported $1.22 EPS for the quarter, topping the consensus estimate of ($1.01) by $2.23. The business had revenue of $132.01 million during the quarter, compared to analyst estimates of $10.73 million. Prothena had a negative return on equity of 9.00% and a negative net margin of 23.44%. The company's quarterly revenue was up 3184.7% on a year-over-year basis. During the same period last year, the business posted ($1.03) earnings per share. Research analysts anticipate that Prothena Co. plc will post -2.34 earnings per share for the current year.
Institutional Trading of Prothena
A number of institutional investors and hedge funds have recently bought and sold shares of the business. DCF Advisers LLC lifted its stake in Prothena by 0.5% in the second quarter. DCF Advisers LLC now owns 107,500 shares of the biotechnology company's stock worth $2,219,000 after acquiring an additional 500 shares during the last quarter. Signaturefd LLC boosted its position in shares of Prothena by 182.1% during the 2nd quarter. Signaturefd LLC now owns 1,337 shares of the biotechnology company's stock worth $28,000 after acquiring an additional 863 shares in the last quarter. ProShare Advisors LLC increased its holdings in shares of Prothena by 8.9% in the 1st quarter. ProShare Advisors LLC now owns 11,346 shares of the biotechnology company's stock valued at $281,000 after acquiring an additional 932 shares during the last quarter. PNC Financial Services Group Inc. raised its position in shares of Prothena by 265.9% during the 4th quarter. PNC Financial Services Group Inc. now owns 1,544 shares of the biotechnology company's stock worth $56,000 after acquiring an additional 1,122 shares in the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank lifted its stake in Prothena by 13.1% during the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 10,236 shares of the biotechnology company's stock worth $211,000 after purchasing an additional 1,186 shares during the last quarter. 97.08% of the stock is currently owned by hedge funds and other institutional investors.
Prothena Company Profile
(
Get Free Report)
Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson's disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer's disease.
Further Reading
Before you consider Prothena, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Prothena wasn't on the list.
While Prothena currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
